The value of plasma exosome HSP90α in predicting colorectal cancer liver metastasis

doi:10.3877/cma.j.issn.2095-3224.2021.02.010

Abstract

Abstract:

Objective

To explore the relationship between plasma exosome HSP90α and colorectal cancer liver metastasis in patients with colorectal cancer.

Methods

The differential expression levels of plasma free HSP90α and exosome HSP90α extracted by ultracentrifugation method were detected by ELISA in 27 patients with stage I-III primary colorectal cancer (pCRC) and 27 patients with colorectal cancer liver metastasis (CRLM).

Results

Ultracentrifugation method can effectively extract plasma exosomes, which have been verified to meet the relevant characteristics of exosomes. The expression level of plasma exosome HSP90α in CRC patients is related to the degree of tumor site (H=6.426, P＜0.05). The expression levels of plasma exosome HSP90α in CRLM group were significantly higher than those in pCRC group (Z=2.898, P＜0.05), which is consistent with the expression trend of plasma free HSP90α. Multivariate logistics regression analysis showed that plasma exosomes HSP90α, plasma free HSP90α, and CEA were independent risk factors for the diagnosis of colorectal cancer and liver metastasis (P＜0.05). And plasma exosome HSP90α combined with CEA has the highest diagnostic efficiency.

Conclusion

Exosome HSP90α may be related to the biological function of colorectal cancer liver metastasis, and can be used as an effective supplement to traditional markers.

Key words: Colorectal neoplasms, Metastasis, Exosome, HSP90α, ELISA

Jiahui Zhou, Sitong Chen, Haizhou Liu, Wen'e Wei, Litu Zhang. The value of plasma exosome HSP90α in predicting colorectal cancer liver metastasis[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(02): 172-176.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2021.02.010

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2021/V10/I02/172

Figures/Tables 4

References 20

1	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A cancer Journal for Clinicians, 2018, 68(6): 394-424.
2	石援援, 薄晓通, 董翠梅, 等. 结直肠癌患者血清CEA、CA199的表达变化与肝转移的多因素相关性分析[J]. 肿瘤药学, 2018, 8(3): 387-391.
3	吴娟, 郑丹, 阮丽蒽, 等. 多项肿瘤标志物联合检测在胃肠道肿瘤诊断中的价值[J]. 标记免疫分析与临床, 2020, 27(1): 10-14+18.
4	罗永章. 血浆Hsp90α是一个全新的肿瘤标志物[C]. 遵循诊疗规范、鼓励临床试验——第八届中国肿瘤内科大会、第三届中国肿瘤医师大会、中国抗癌协会肿瘤临床化疗专业委员会2014年学术年会, 2014: 3.
5	刘媛芳, 利基林, 梁新强, 等. TK1、HSP90α联合CEA、CA199检测在结直肠癌临床诊断中的意义[J]. 药物生物技术, 2019, 26(6): 498-501.
6	Kalluri R. The biology and function of exosomes in cancer[J]. J Clin Invest, 2016, 126(4): 1208-1215.
7	Steinbichler TB, Dudas J, Riechelmann H, et al. The role of exosomes in cancer metastasis[J]. Semin Cancer Biol, 2017, 44: 170-181.
8	Zaborowski MP, Balaj L, Breakefield XO, et al. Extracellular vesicles: composition, biological relevance, and methods of study[J]. Bioscience, 2015, 65(8): 783-797.
9	Taha EA, Ono K, Eguchi T. Roles of extracellular HSPs as biomarkers in immune surveillance and immune evasion[J]. International journal of molecular sciences, 2019, 20(18): 4588.
10	Cheng CF, Fan JF, Fedesco M, et al. Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing[J]. Molecular and cellular biology, 2008, 28(10): 3344-3358.
11	刘荫华, 姚宏伟, 周斌, 等. 美国肿瘤联合会结直肠癌分期系统(第8版)更新解读[J]. 中国实用外科杂志, 2017, 37(1): 6-9.
12	Jan L, Andrew FH, Fred H, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles[J]. Journal of Extracellular Vesicles, 2014, 3: 26913.
13	Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer[J]. Ann Surg, 2006, 244(2): 254-259.
14	Shi Y, Liu X, Lou J, et al. Plasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responses[J]. Clin Cancer Res, 2014, 20(23): 6016-6022.
15	Liu W, Li J, Zhang P, et al. A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic[J]. Cancer Sci, 2019, 110(9): 2941-2959.
16	Zhang S, Guo S, Li Z, et al. High expression of HSP90 is associated with poor prognosis in patients with colorectal cancer[J]. PeerJ, 2019, 7: e7946.
17	Abramowicz A, Widlak P, Pietrowska M. Proteomic analysis of exosomal cargo: the challenge of high purity vesicle isolation[J]. Mol Biosyst, 2016, 12(5): 1407-1419.
18	Ding M, Wang C, Lu X, et al. Comparison of commercial exosome isolation kits for circulating exosomal microRNA profiling[J]. Anal Bioanal Chem, 2018, 410(16): 3805-3814.
19	Li W, Li Y, Guan S, et al. Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing[J]. Embo J, 2007, 26(5): 1221-1233.
20	Ostroff RM, Bigbee WL, Franklin W, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer[J]. PLoS One, 2010, 5(12): e15003.

临床病理特征	例数	血浆游离HSP90α（ng/mL）	检验值	P值	血浆外泌体HSP90α（ng/mL）	检验值	P值
年龄（岁）			-0.553	0.580		-1.569	0.117
≤50	14	85.15（22.60~427.00）			48.30（15.52~248.00）
＞50	40	78.95（15.08~524.00）			36.75（5.94~147.30）
性别			-1.496	0.135		-1.664	0.096
男	32	97.20（15.08~524.00）			45.20（5.94~147.30）
女	22	65.90（16.94~172.70）			28.46（7.49~248.00）
部位			2.582	0.275		6.426	0.040
左半结肠	13	113.40（22.60~524.00）			43.60（10.82~147.30）
右半结肠	14	84.50（34.70~522.00）			50.30（18.10~248.00）
直肠	27	73.90（15.08~290.00）			32.25（5.94~132.00）
分化程度			1.202	0.548		4.366	0.113
低	3	88.90（42.20~132.00）			65.55（25.60~132.00）
中	47	45.40（10.82~248.00）			42.60（5.94~248.00）
高	4	47.33（35.40~101.40）			24.23（9.76~49.20）
CEA			-0.569	0.570		-0.376	0.707
≤5 ng/mL	23	89.60(15.08~522.00)			32.86（6.80~131.40）
＞5 ng/mL	31	77.30(16.53~524.00)			43.60（5.94~248.00）
临床分期			-3.036	0.002		-2.898	0.004
Ⅰ~Ⅲ期（原发结直肠癌）	27	48.70（15.08~172.70）			27.74（5.94~62.60）
Ⅳ（结直肠癌肝转移）	27	107.80（22.60~524.00）			45.40（10.82~248.00）

临床病理特征	例数	血浆游离HSP90α（ng/mL）	检验值	P值	血浆外泌体HSP90α（ng/mL）	检验值	P值
年龄（岁）			-0.553	0.580		-1.569	0.117
≤50	14	85.15（22.60~427.00）			48.30（15.52~248.00）
＞50	40	78.95（15.08~524.00）			36.75（5.94~147.30）
性别			-1.496	0.135		-1.664	0.096
男	32	97.20（15.08~524.00）			45.20（5.94~147.30）
女	22	65.90（16.94~172.70）			28.46（7.49~248.00）
部位			2.582	0.275		6.426	0.040
左半结肠	13	113.40（22.60~524.00）			43.60（10.82~147.30）
右半结肠	14	84.50（34.70~522.00）			50.30（18.10~248.00）
直肠	27	73.90（15.08~290.00）			32.25（5.94~132.00）
分化程度			1.202	0.548		4.366	0.113
低	3	88.90（42.20~132.00）			65.55（25.60~132.00）
中	47	45.40（10.82~248.00）			42.60（5.94~248.00）
高	4	47.33（35.40~101.40）			24.23（9.76~49.20）
CEA			-0.569	0.570		-0.376	0.707
≤5 ng/mL	23	89.60(15.08~522.00)			32.86（6.80~131.40）
＞5 ng/mL	31	77.30(16.53~524.00)			43.60（5.94~248.00）
临床分期			-3.036	0.002		-2.898	0.004
Ⅰ~Ⅲ期（原发结直肠癌）	27	48.70（15.08~172.70）			27.74（5.94~62.60）
Ⅳ（结直肠癌肝转移）	27	107.80（22.60~524.00）			45.40（10.82~248.00）

pCRC vs. CRLM	OR	95%CI	P值
血浆HSP90α	1.019	1.000~1.037	0.049
外泌体HSP90α	1.053	1.005~1.105	0.032
CEA	31.035	3.655~263.488	0.002

pCRC vs. CRLM	OR	95%CI	P值
血浆HSP90α	1.019	1.000~1.037	0.049
外泌体HSP90α	1.053	1.005~1.105	0.032
CEA	31.035	3.655~263.488	0.002

pCRC vs. CRLM	AUC	敏感性（%）	特异性（%）	截断值	95%CI	P值
CEA	0.838	77.78	77.78	5.65	0.713~0.924	＜0.0001
血浆HSP90α	0.741	85.19	51.85	48.7	0.603~0.850	0.0004
外泌体HSP90α	0.73	74.07	66.67	40.4	0.592~0.842	0.0008
血浆HSP90α+CEA	0.83	62.96	96.3	0.593	0.703~0.918	＜0.0001
外泌体HSP90α+CEA	0.861	66.67	92.59	0.593	0.740~0.940	＜0.0001

Please choose a citation manager

Content to export